News headlines about Corcept Therapeutics (NASDAQ:CORT) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corcept Therapeutics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8252582594691 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Corcept Therapeutics (CORT) Lifted to “Strong-Buy” at BidaskClub (americanbankingnews.com)
- 10 Healthcare Stocks to Stave Off the Market Flu (finance.yahoo.com)
- Corcept Therapeutics (CORT) Now Covered by Seaport Global Securities (americanbankingnews.com)
- Stocks With Rising Relative Price Strength: Corcept Therapeutics (investors.com)
- JF’s Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position (seekingalpha.com)
Shares of CORT stock opened at $17.10 on Tuesday. The company has a market cap of $1,949.82, a P/E ratio of 38.86 and a beta of 1.88. Corcept Therapeutics has a 12 month low of $8.90 and a 12 month high of $25.96.
A number of research analysts have weighed in on CORT shares. Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Piper Jaffray set a $30.00 target price on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Monday, February 5th. Stifel Nicolaus dropped their target price on shares of Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, February 5th. Finally, B. Riley started coverage on shares of Corcept Therapeutics in a research note on Thursday, March 8th. They issued a “buy” rating and a $30.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $24.33.
In other Corcept Therapeutics news, Director Renee D. Gala purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 7th. The shares were bought at an average cost of $15.51 per share, for a total transaction of $155,100.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $15,510. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, April 6th. The shares were sold at an average price of $16.22, for a total transaction of $129,760.00. Following the sale, the insider now owns 8,000 shares in the company, valued at $129,760. The disclosure for this sale can be found here. Insiders have sold a total of 24,000 shares of company stock worth $387,920 over the last 90 days. 19.20% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2018/04/17/corcept-therapeutics-cort-receives-coverage-optimism-rating-of-0-09.html.
About Corcept Therapeutics
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.